在治疗贫症时发生缺血性中风:关于三例病例的报告
Naohiro Uchio1, Shogo Komaki1, Akihito Hao1
1Department of Neurology, Mitsui Memorial Hospital, Tokyo, JPN.
Cureus
|May 13, 2024
概括
低氧诱导因子酸酶 (HIF-PH) 抑制剂,如达普罗多斯塔特,可在贫血患者中引起缺血性中风. 停止服用达普罗杜斯塔特可以降低中风风险,尤其是在血红蛋白水平高的情况下.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脏贫血通常用低氧诱导因子酸酶 (HIF-PH) 抑制剂治疗.
- 缺血性中风是一种罕见但严重的不良事件,与HIF-PH抑制剂治疗有关.
- 与HIF-PH抑制剂相关的缺血性中风的临床特征仍然没有被描述.
研究的目的:
- 描述在接受HIF-PH抑制剂达普罗杜斯塔特治疗的患者中缺血性中风的临床特征.
- 为了确定与达普罗德斯塔特诱导的缺血性中风相关的风险因素和结果.
主要方法:
- 三名患有非透析依赖慢性病 (CKD) 的患者在达普罗德斯塔特治疗期间发生缺血性中风的病例报告.
- 分析患者数据,包括血红蛋白水平,中风发病时间相对于达普罗杜斯塔开始,以及停止治疗后的结果.
主要成果:
- 三名患者中有两名的血红蛋白水平超过了13g/dL的推目标.
- 在两名患者中,达普罗杜斯塔特在服用达普罗杜斯塔特后两个月内发生缺血性中风.
- 在三位患者中,在停止服用达普罗杜斯塔特后,没有观察到中风复发.
结论:
- 达普罗多斯塔特治疗是缺血性中风的潜在危险因素,特别是在血红蛋白过高或治疗早期.
- 停止使用达普罗杜斯塔特对于减轻复发性缺血性中风的风险至关重要.
- 需要进一步的研究,以充分了解HIF-PH抑制剂相关的缺血性中风的机制和发病率.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:11Renal Failure: Dose Adjustments
85
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
85
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521